ALK Immunohistochemistry in NSCLC: Discordant Staining Can Impact Patient Treatment Regimen

Journal of Thoracic Oncology

Volumn 11, Issue 12, 2016, Pages 2241-2247

  Ibrahim, Merdol ^a   Parry, Suzanne ^a   Wilkinson, Dawn ^a   Bilbe, Neil ^a   Allen, David ^a   Forrest, Steven ^b   Maxwell, Perry ^c   O'Grady, Anthony ^d   Starczynski, Jane ^e   Tanier, Philippe ^f   Gosney, John ^b   Kerr, Keith ^g   Miller, Keith ^a   Thunnissen, Erik ^h  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^d BEAUMONT HOSPITAL   (Ireland)

^e BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^f QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^g ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ALK IHC; External quality assessment; Immunohistochemistry; NSCLC

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; PROTEIN TYROSINE KINASE;

ALK GENE; ANTIBODY DETECTION; CANCER SCREENING; CLINICAL PROTOCOL; CONTROLLED STUDY; EVIDENCE BASED MEDICINE; FALSE NEGATIVE RESULT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NON SMALL CELL LUNG CANCER; REVIEW; SCORING SYSTEM; SELF EVALUATION; SENSITIVITY ANALYSIS; IMMUNOLOGY; PROCEDURES;

HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 85010831581     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.07.012     Document Type: Article

References (15)

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108.
2. Thomas A, Liu SV, Subramaniam DS, et al. Refining the treatment of NSCLC according to histological and molecular subtypes. Nat Rev Clin Oncol. 2015;12:511-526.
3. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561-566.
4. Marchetti A, Di Lorito A, Pace MV, et al. ALK protein analysis by IHC staining after recent regulatory changes: a comparison of two widely used approaches, revision of the literature, and a new testing algorithm. J Thorac Oncol. 2016;11:487-495.
5. Blackhall FH, Peters S, Bubendorf L, et al. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. J Clin Oncol. 2014;32:2780-2787.
6. Savic S, Diebold J, Zimmermann AK, et al. Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended. Lung Cancer. 2015;89:104-109.
7. Paik JH, Choe G, Kim H, et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol. 2011;6:466-472.
8. von Laffert M, Penzel R, Schirmacher P, et al. Multicenter ALK testing in non-small-cell lung cancer: results of a round robin test. J Thorac Oncol. 2014;9: 1464-1469.
9. Pekar-Zlotin M, Hirsch FR, Soussan-Gutman L, et al. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. Oncologist. 2015;20:316-322.
10. von Laffert M, Warth A, Penzel R, et al. Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria. J Thorac Oncol. 2014;9:1685-1692.
11. Tembuyser L, Tack V, Zwaenepoel K, et al. The relevance of external quality assessment for molecular testing for ALK positive non-small cell lung cancer: results from two pilot rounds show room for optimization. PLoS One. 2014;9:e112159.
12. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALKrearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010;16:1561-1571.
13. Yi ES, Boland JM, Maleszewski JJ, et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol. 2011;6:459-465.
14. Marchetti A, Barberis M, Papotti M, et al. ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: results of the first italian external quality assurance scheme. J Thorac Oncol. 2014;9:1470-1476.
15. Hutarew G, Hauser-Kronberger C, Strasser F, et al. Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH. Histopathology. 2014;65:398-407.